Statera Biopharma, Inc. (STAB) stock experiencing downfall of 16.03% – What’s the reason?
Mahrukh Rehan
February 7, 2022
Statera Biopharma, Inc. (STAB) saw a decrease of 16.03% in premarket because the company announced the pricing of $2.0 Million Registered Direct Offering. However, the